Divalproex sodium is a Food and Drug Administrator (FDA) approved anti-epileptic drug used to treat migraine headaches, manic episodes of bipolar disorders, and certain types of seizures. Divalproex sodium is known for its anticonvulsant properties for the treatment of epilepsy. Divalproex sodium comes under three dosage forms: capsule, tablet, and syrup. Divalproex sodium oral tablet is available in brand-names, Depakote ER and Depakote. Divalproex sodium is also used in various combinational therapies.
Click To Continue Reading on Divalproex Sodium Market
The recommended initial dosage of Depakote for the treatment of bipolar disorders is 750 mg daily, whereas for complex partial seizures, initial dosage starts with 10 to 15 mg/kg/day. Also, recommended starting dose for migraine headache is 250 mg twice daily to achieve therapeutic response.
For instance, according to study published in JAMA Psychiatry Journal 2012, in a combined sample of 61,392 adults from 11 countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and 0.4% for bipolar disorder-II and subthreshold bipolar disorder was 1.4%, yielding a total prevalence estimates bipolar disorder spectrum of 2.4% globally.
Moreover, rising patient pool around the world affected with epilepsy and migraine headaches is also expected to boost demand for divalproex sodium market significantly. For instance, according to the World Health Organization 2018 key facts, around 50 million people were globally affected with epilepsy, making it one of the most common neurological disease, and around 80% of the people with epilepsy live in low- and middle-income countries. According to The Migraine Trust Facts and Figures estimates, the global prevalence of migraine was 14.7% for year 2013, that’s around 1 in 7 people. Furthermore, increasing awareness regarding diseases and various government initiatives to prevent head migraine is expected to propel growth of divalproex sodium market size.
However, black boxed warning given by FDA due to the hepatotoxicity, pancreatitis, and high fetal risk associated with the use of divalproex sodium tablet and other known adverse reactions such as birth defects, neurobehavioral adverse effects, and suicidal behavior are expected to restrain the divalproex sodium market growth. Based on the region, the global divalproex sodium market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America, specifically the U.S. divalproex sodium market, holds a major global position among the geographies. Owing to increased government initiatives and rising research and development for the introduction of new product are expected to aid in growth of the divalproex sodium market in the region.
For instance, In 2011 The National Quality Strategy (NQS) was launched as the national strategy for quality improvement in health care, This was led by Agency for Healthcare Research and Quality on behalf of the U.S. Department of Health and Human Services (HHS). However, introduction of generic products by market giants in the region is expected to hamper the market growth in the region. For instance, in 2008, Mylan launched generic of Abbott’s Depakote ER in the U.S.